Browse Studies — Arctuva

Phase 3

A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism

This trial has a treatment duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 3…

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases

Estimated

~$10 – $8,750

Ascendis Pharma Bone Diseases A/SNCT07081997

A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical resear…

Age-Related Macular DegenerationAllergiesAlpha-Gal Syndrome+44 more

Estimated

~$10 – $1,050

Sanguine BiosciencesNCT05635266

Phase 2

A Multicenter, Extension Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were enrolled i…

Thyroid Eye DiseaseGraves OrbitopathyEndocrine System Diseases+9 more

Estimated

~$10 – $8,750

Sling Therapeutics, Inc.NCT06112340